New-look Sarepta eyes approval for muscular dystrophy drug
April 02, 2013 at 13:51 PM EDT
* Under new CEO, Sarepta focused on Duchenne muscular dystrophy drug
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.